A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

Clinical trial NCT03516071 · COMPLETED

Trial details

NCT number: NCT03516071
Sponsor: Zai Lab (Shanghai) Co., Ltd.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma (HCC)

Start date: 2017-05-17
Primary completion: 2018-11-09
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.